ASN to Spotlight Debate around Ardelyx's Embattled CKD Drug

On Nov.16, the FDA’s Cardiovascular and Renal Drug Advisory Committee will meet to assess the data supporting Ardelyx's New Drug Application for tenapanor in chronic kidney disease.